Phathom Pharmaceuticals Inc (PHAT) Stock Price & News

PHAT:NASDAQ

Phathom Pharmaceuticals Inc

5,68 USD

-1,05%

(-0,060) 1D

5,68 USD

0,00% (0,00)

After hours

Closed: 4-ноя., 16:00:01 GMT-5 · USD

All symbols

	Symbol	Price	Change	% Change

Generating top insights for PHAT...

Open

5,95 USD

High

6,13 USD

Low

5,66 USD

Mkt. cap

461,74 млн

Avg. vol.

1,63 млн

Volume

1,51 млн

52-wk high

18,31 USD

52-wk low

5,02 USD

EPS

-1,03 USD

Beta

0,69

Shares outstanding

81,29 млн

No. of employees

371

Open

5,95 USD

High

6,13 USD

Low

5,66 USD

Mkt. cap

461,74 млн

Avg. vol.

1,63 млн

Volume

1,51 млн

52-wk high

18,31 USD

52-wk low

5,02 USD

EPS

-1,03 USD

Beta

0,69

Shares outstanding

81,29 млн

No. of employees

371

Related stocks

Banzai International Inc

0,32 USD

-88,27%

RIVN

Rivian Automotive Inc

14,06 USD

+5,79%

DNA

Ginkgo Bioworks Holdings Inc

11,65 USD

+8,27%

News stories

From web sources and news partners

Yahoo Finance

45 мүнөт мурун

Dow, S&P 500, Nasdaq Futures Mixed After A Democratic Sweep In Midterms: NVDA, MU, SNDK, NBIS, IREN In Focus

WXOW

19 мүнөт мурун

Dow has best post-midterm elections day in 44 years as Democrats take control of Congress

www.marketscreener.com

20 мүнөт мурун

Backblaze Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

PBS

7 саат мурун

U.S. stocks surge, and the Dow soars 1,500 points as Brent oil's price drops below $95 per barrel

About Phathom Pharmaceuticals Inc

CEO-

Employees371

Founded2018

HeadquartersФлорхем Парк, Нью Джерси, Америка Кошмо Штаттары

SectorPharmaceutical industry

Industry-

Websitephathompharma.com

Analyst	Recommendation	Action	Price target	Projected	Date
Daniel Clark Leerink Partners	Hold	Maintained	7,50 USD	+32%	11/02/2026
Yatin Suneja Guggenheim	Buy	Reiterated	22,00 USD	+287,3%	10/29/2026
Matthew Caufield H.C. Wainwright	Buy	Reiterated	26,00 USD	+357,7%	10/30/2026
Jenna Davidner Barclays	Buy	Maintained	14,00 USD	+146,5%	10/30/2026
Kristen Kluska Cantor Fitzgerald	Buy	Maintained	-	-	10/23/2026
Chase Knickerbocker Craig-Hallum	Buy	Maintained	15,00 USD	+164,1%	10/21/2026
Martin Auster Raymond James	Buy	Maintained	21,00 USD	+269,7%	07/31/2026
Joseph Stringer Needham	Buy	Maintained	22,00 USD	+287,3%	07/30/2026
Paul Choi Goldman Sachs	Hold	Maintained	-	-	04/30/2026

All values in USD	2025-ж. дек.	2026-ж. мар.	2026-ж. июн.	2026-ж. сен.
Revenue	57,58 млн	58,30 млн	74,27 млн	84,72 млн
Cost of goods sold	7,65 млн	12,00 млн	15,10 млн	18,37 млн
Cost of revenue	7,65 млн	12,00 млн	15,10 млн	18,37 млн
Research and development expenses	7,49 млн	7,77 млн	7,81 млн	8,74 млн
Total research and development expenses	-	-	-	-
Selling, general, and admin expenses	48,37 млн	54,01 млн	55,33 млн	57,70 млн
Operating expense	55,86 млн	61,78 млн	63,14 млн	66,44 млн
Total operating expenses	63,51 млн	73,78 млн	78,24 млн	84,81 млн
Operating income	-5,93 млн	-15,48 млн	-3,96 млн	-85,00 миң
Other non operating income	-5,00 миң	-831,00 миң	-24,00 миң	-25,00 миң
EBT including unusual items	-21,15 млн	-30,37 млн	-17,58 млн	-13,90 млн
EBT excluding unusual items	-21,15 млн	-30,37 млн	-17,58 млн	-13,90 млн
Income tax expense	-	-	-	-
Effective tax rate	-	-	-	-
Other operating expenses	-	-	-	-
Net income	-21,15 млн	-30,37 млн	-17,58 млн	-13,90 млн
Net profit margin	-36,73%	-52,09%	-23,67%	-16,40%
Earnings per share	-0,08	-0,18	-	0,04
Interest and investment income	1,20 млн	1,74 млн	1,51 млн	1,60 млн
Interest expense	-16,42 млн	-15,80 млн	-15,10 млн	-15,39 млн
Net interest expenses	-15,22 млн	-14,06 млн	-13,59 млн	-13,79 млн
Depreciation and amortization charges	-	-	-	-
EBITDA	-5,80 млн	-15,37 млн	-3,85 млн	35,00 миң
Gain or loss from assets sale	-	-	-	-

Ask anything